1
|
De Rose F, Di Brina L, Mussari S, Ravanelli D, Magri E, Proto T, Bandera L, Ferrazza P, Fersino S, Andolina M, Ziglio F, Delana A, Martignano A, Menegotti L, Bou Selman S, Vanoni V. PO-1191 WBI and IORT for breast cancer: long-term results of a large mono-institution matched-pair analysis. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03155-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
2
|
Maffei N, Manco L, Aluisio G, D'Angelo E, Ferrazza P, Vanoni V, Meduri B, Lohr F, Guidi G. Radiomics classifier to quantify automatic segmentation quality of cardiac sub-structures for radiotherapy treatment planning. Phys Med 2021; 83:278-286. [DOI: 10.1016/j.ejmp.2021.05.009] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/15/2020] [Revised: 04/30/2021] [Accepted: 05/03/2021] [Indexed: 12/24/2022] Open
|
3
|
Campitelli M, Lazzari R, Piccolo F, Ferrazza P, Marsella AR, Macchia G, Fodor A, Santoni R, Tagliaferri L, Cerrotta A, Aristei C. Brachytherapy or external beam radiotherapy as a boost in locally advanced cervical cancer: a Gynaecology Study Group in the Italian Association of Radiation and Clinical Oncology (AIRO) review. Int J Gynecol Cancer 2021; 31:1278-1286. [PMID: 33632703 DOI: 10.1136/ijgc-2020-002310] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2020] [Revised: 01/29/2021] [Accepted: 02/03/2021] [Indexed: 11/04/2022] Open
Abstract
This review analyzes the experience and trends in external beam radiotherapy for delivering a boost in locally advanced cervical cancer, identifying whether radiation therapy modalities impact clinical outcomes with the ultimate aim of evaluating alternatives to brachytherapy. Three independent Italian radiation oncologists conducted a literature search on different external beam radiotherapy boost modalities in locally advanced cervical cancer. The search yielded 30 studies. Eight dosimetric studies, evaluating target coverage and dose to organs at risk, and nine clinical investigations, reporting clinical outcomes, were analyzed. Dosimetric studies comparing external beam radiotherapy boost with brachytherapy produced divergent results, while clinical studies were limited by their retrospective nature, heterogeneous doses, radiation schedules, volumes and techniques, diverse follow-up times, and small cohorts of patients. Evidence emerged that high-tech external beam radiotherapy seemed no better than image-guided brachytherapy for delivering a boost in locally advanced cervical cancer. Prospective clinical studies comparing high-tech external beam radiotherapy and image-guided brachytherapy should be encouraged.
Collapse
Affiliation(s)
- Maura Campitelli
- Dipartimento di Scienze Radiologiche, Radioterapiche ed Ematologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC di Radioterapia, Rome, Italy
| | - Roberta Lazzari
- Department of Radiotherapy, IEO, European Institute of Oncology IRCCS, Milano, Lombardia, Italy
| | - Federica Piccolo
- Radiotherapy Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy
| | | | | | - Gabriella Macchia
- Radiotherapy Unit, Gemelli Molise Hospital, Università Cattolica del Sacro Cuore, Campobasso, Italy
| | - Andrei Fodor
- Department of Radiation Oncology, IRCCS San Raffaele Scientific Institute, Milano, Italy
| | - Riccardo Santoni
- Department of Biomedicine and Prevention, University of Rome Tor Vergata, UNIROMA2, Rome, Italy
| | - Luca Tagliaferri
- Dipartimento di Scienze Radiologiche, Radioterapiche ed Ematologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC di Radioterapia, Rome, Italy
| | - Annamaria Cerrotta
- Radiotherapy Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy
| | - Cynthia Aristei
- Radiation Oncology Section, University of Perugia and Perugia General Hospital, Perugia, Umbria, Italy
| |
Collapse
|
4
|
Maffei N, Fiorini L, Aluisio G, D'Angelo E, Ferrazza P, Vanoni V, Lohr F, Meduri B, Guidi G. Hierarchical clustering applied to automatic atlas based segmentation of 25 cardiac sub-structures. Phys Med 2020; 69:70-80. [DOI: 10.1016/j.ejmp.2019.12.001] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/16/2019] [Revised: 10/24/2019] [Accepted: 12/01/2019] [Indexed: 01/07/2023] Open
|
5
|
Delana A, Vanoni V, Ferrazza P, Coelli F, Maino M. EP-1984 Cone beam computed tomography (CBCT) interobserver variability in patient setup error evaluation. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)32404-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
6
|
Ferrazza P, De Renzi F, Iannone T. EP-1161: Hypofracionated Radiation Therapy in Breast Cancer: retrospective analysis of late toxicity. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)31597-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
7
|
Grespi S, Menichelli C, Fanelli A, Ferrazza P, Pastore G, Frallicciardi P, Casamassima F. Stereotactic Body Radiation for Treatment of Oligometastatic Renal Cell Cancer. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.1338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
8
|
Ferrazza P, Menichelli C, Fanelli A, Grespi S, Pastore G, Frallicciardi P, Casamassima F. Thoracic Reirradiation After Previous Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer and Lung Metastases: The Role of Ablative Radiation Therapy. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.1808] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
9
|
Ursino S, Faggioni L, Guidoccio F, Ferrazza P, Seccia V, Neri E, Cernusco LN, Delishaj D, Morganti R, Volterrani D, Paiar F, Caramella D. Role of perfusion CT in the evaluation of functional primary tumour response after radiochemotherapy in head and neck cancer: preliminary findings. Br J Radiol 2016; 89:20151070. [PMID: 27377172 DOI: 10.1259/bjr.20151070] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
OBJECTIVE To report the initial results of a prospective study aimed at evaluating the CT perfusion parameter changes (∆PCTp) of the primary tumour after radiochemotherapy (RCT) in head and neck cancer (HNC) and to correlate with positron emission tomography (PET)/CT response. METHODS Eligibility criteria included HNC (Stage III-IV) candidates for RCT. Patients underwent perfusion CT (PCT) at baseline and at 3 weeks and 3 months after treatment. Blood volume, blood flow, mean transit time (MTT) and permeability surface (PS) product were computed. Moreover, PET/CT was performed at baseline and 3 months after treatment. The ∆PCTp were evaluated between baseline and 3-week/3-month evaluations, whereas PET/CT response was based on the maximum standardized uptake value changes according to the European Organization for Research and Treatment of Cancer criteria. RESULTS Between July 2012 and July 2015, 25 patients were enrolled. A significant reduction of all CT tumour perfusion parameters (PCTp) was observed from the baseline to after RCT (p < 0.001). Specifically, a significant reduction was shown at 3 weeks for all PCTp except MTT (from 6.18 to 5.14 s; p = 0.722). Differently, a significant reduction of all PCTp (p < 0.001) including MTT (from 6.18 to 2.24 s; p = 0.001) was shown at 3 months. Moreover, the reduction of PS resulted in a significant prediction of PET/CT response at 3 months (p = 0.037) with the trend also at 3 weeks (p = 0.099) at the multivariate analysis. CONCLUSION Our preliminary findings seem to show that almost all PCTp are significantly reduced after RCT, whereas PS seems to come out as the strongest factor in predicting the PET/CT response. ADVANCES IN KNOWLEDGE This article provides information on the potential useful role of PCT in evaluating tumour response after both early and late RCT.
Collapse
Affiliation(s)
- Stefano Ursino
- 1 Department of Radiation Oncology, University Hospital S. Chiara, Pisa, Italy
| | - Lorenzo Faggioni
- 2 Department of Radiology, University Hospital Cisanello, Pisa, Italy
| | - Federica Guidoccio
- 3 Department of Nuclear Medicine, University Hospital S.Chiara, Pisa, Italy
| | - Patrizia Ferrazza
- 1 Department of Radiation Oncology, University Hospital S. Chiara, Pisa, Italy
| | - Veronica Seccia
- 4 First Otorhinolaryngology Unit, University Hospital Cisanello, Pisa, Italy
| | - Emanuele Neri
- 2 Department of Radiology, University Hospital Cisanello, Pisa, Italy
| | - Luna N Cernusco
- 1 Department of Radiation Oncology, University Hospital S. Chiara, Pisa, Italy
| | - Durim Delishaj
- 1 Department of Radiation Oncology, University Hospital S. Chiara, Pisa, Italy
| | - Riccardo Morganti
- 5 Biostatistical Consulting, Department of Oncology, University Hospital S.Chiara, Pisa, Italy
| | - Duccio Volterrani
- 3 Department of Nuclear Medicine, University Hospital S.Chiara, Pisa, Italy
| | - Fabiola Paiar
- 1 Department of Radiation Oncology, University Hospital S. Chiara, Pisa, Italy
| | - Davide Caramella
- 2 Department of Radiology, University Hospital Cisanello, Pisa, Italy
| |
Collapse
|
10
|
Grespi S, Menichelli C, Fanelli A, Ferrazza P, Pastore G, Casamassima F. EP-1379: SBRT in the treatment of bone metastases in hormone refractary prostate cancer. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)32629-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
11
|
Menichelli C, Pastore G, Fanelli A, Grespi S, Ferrazza P, Chella A, Petrini I, Casamassima F. EP-1253: Local control and toxicity for centrally located NSCLC: SABR in no fly zone. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)32503-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
12
|
Pasqualetti F, Panichi M, Sainato A, Matteucci F, Derosa L, Cocuzza P, Coraggio G, Ferrazza P, Montrone S, Cantarella M, Delishaj D, Cristaudo A, Fabrini M, Greco C, Erba P. PO-0756: Choline PET/CT and Stereotactic Body Radiotherapy in oligometastatic prostate cancer patients. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)32006-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
13
|
Ferrazza P, Cocuzza P, Pancrazi F, Delishaj D, Fatigante L, Cristaudo A, Faggioni L, Orlandi F, Matteucci F, Ursino S. EP-1104: Role of perfusion CT in evaluation of tumour response after radiochemotherapy in H&N cancer. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)32354-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
14
|
Ursino S, Seccia V, Cocuzza P, Ferrazza P, Briganti T, Matteucci F, Fatigante L, Giusti P, Grosso M, Locantore L, Morganti R, Nacci A, Sellari Franceschini S, Paiar F, Caramella D, Fattori B. How does radiotherapy impact swallowing function in nasopharynx and oropharynx cancer? Short-term results of a prospective study. Acta Otorhinolaryngol Ital 2016; 36:174-84. [PMID: 27070541 PMCID: PMC4967765 DOI: 10.14639/0392-100x-640] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/11/2015] [Accepted: 02/02/2016] [Indexed: 12/14/2022]
Abstract
The objective of this study is to report the initial results of a prospective trial assessing instrumental deglutition function in nasopharynx and oropharynx cancers after radio or chemoradiotherapy using intensity-modulated radiotherapy (IMRT). IMRT was delivered aiming to spare the swallowing organ at risk (SWOARs) for Stage II-IV naso- and oropharynx cancer. Objective instrumental assessment included videofluoroscopy (VFS), fiberoptic endoscopic evaluation of swallowing (FEES) and oro-pharyngeal-oesophageal scintigraphy (OPES) at baseline and at 1 month after radiotherapy. Dysphagia parameter scores were calculated at each exam after liquid (L) and semi-liquid (SL) bolus intake: pre-deglutition penetration, aspiration, pharyngeal transit time (PTT) and hypopharyngeal retention index (HPRI). Overall, 20 patients (6 nasophaynx and 14 oropharynx) completed treatment and instrumental assessment after 1 month. Comparison between pre- and post-treatment HPRI score values showed a significant worsening in both FEES-L (p = 0.021) and SL (p = 0.02) and at VFS-L (p = 0.008) and SL (p = 0.005). Moreover, a relationship between HPRI worsening at FEES-L and FEES-SL (p = 0.005) as well as at VFS-L and VFS-SL (p < 0.001) was observed. PTT was not significantly affected by radiotherapy (p > 0.2). Only a few patients experienced pre-deglutition penetration (1 patient with base of tongue cancer at FEES-L and SL) and aspiration (1 patient with nasopharynx cancer at OPES-L and FEES-SL) after radiotherapy. Our early results showed that IMRT-SWOARs sparing caused a significant increase in the post-deglutition HPRI score. Longer follow-up will be necessary to evaluate if the increase of HPRI is related to a high risk of developing late aspiration.
Collapse
Affiliation(s)
- S Ursino
- Department of Radiation Oncology, University Hospital S. Chiara, Pisa, Italy
| | - V Seccia
- First Otorhinolaryngology Unit, University Hospital Cisanello, Pisa, Italy
| | - P Cocuzza
- Department of Radiation Oncology, University Hospital S. Chiara, Pisa, Italy
| | - P Ferrazza
- Department of Radiation Oncology, University Hospital S. Chiara, Pisa, Italy
| | - T Briganti
- First Otorhinolaryngology Unit, University Hospital Cisanello, Pisa, Italy
| | - F Matteucci
- Department of Radiation Oncology, University Hospital S. Chiara, Pisa, Italy
| | - L Fatigante
- Department of Radiation Oncology, University Hospital S. Chiara, Pisa, Italy
| | - P Giusti
- Department of Radiology, University Hospital Cisanello, Pisa, Italy
| | - M Grosso
- Department of Nuclear Medicine, University Hospital S. Chiara, Pisa,Italy
| | - L Locantore
- Department of Nuclear Medicine, University Hospital S. Chiara, Pisa,Italy
| | - R Morganti
- Biostatistical Consulting, Department of Oncology, University Hospital S.Chiara, Pisa, Italy
| | - A Nacci
- Otorhinolaryngology-Audiology-Phoniatric Unit, University Hospital Cisanello, Pisa, Italy
| | | | - F Paiar
- Department of Radiation Oncology, University Hospital S. Chiara, Pisa, Italy
| | - D Caramella
- Department of Radiology, University Hospital Cisanello, Pisa, Italy
| | - B Fattori
- Otorhinolaryngology-Audiology-Phoniatric Unit, University Hospital Cisanello, Pisa, Italy
| |
Collapse
|
15
|
Pasqualetti F, Cocuzza P, Coraggio G, Ferrazza P, Derosa L, Galli L, Pasqualetti G, Locantore L, Boni R, Fabrini MG, Erba PA. Long-Term PSA Control with Repeated Stereotactic Body Radiotherapy in a Patient with Oligometastatic Castration-Resistant Prostate Cancer. Oncol Res Treat 2016; 39:217-20. [PMID: 27160394 DOI: 10.1159/000444906] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2015] [Accepted: 01/18/2016] [Indexed: 11/19/2022]
Abstract
Prostate cancer (PCa) is one of the most common malignancies and main causes of cancer death in Western countries. In the presence of metastatic disease, systemic treatment remains the main clinical option. However, since the introduction of highly sensitive imaging techniques, a new clinical 'entity' of metastatic patients with a limited number of lesions has been defined: oligometastatic patients. In this patient group, the use of stereotactic body radiotherapy (SBRT) or other local therapies against all active sites of disease revealed by 18F-choline positron emission tomography/computed tomography (PET/CT) could achieve sufficient prostate-specific antigen (PSA) control. However, a clear benefit of this procedure in terms of significant endpoints is yet to be demonstrated. This case report describes our experience with treating a castration-resistant PCa patient with 18F-choline PET/CT-guided SBRT. Because of the occurrence of 5 metachronous lesions over 4 years, the pattern of recurrence was defined by the local multidisciplinary team as oligometastatic disease, and the patient was treated with 5 courses of SBRT which yielded good PSA control. He started systemic therapy with abiraterone acetate almost 5 years after the diagnosis of recurrent PCa.
Collapse
|
16
|
Pasqualetti F, Panichi M, Sainato A, Matteucci F, Galli L, Cocuzza P, Ferrazza P, Coraggio G, Pasqualetti G, Derosa L, Sollini M, Mannelli L, Ortori S, Monzani F, Ricci S, Greco C, Fabrini MG, Erba PA. [(18)F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results. Radiat Oncol 2016; 11:9. [PMID: 26796633 PMCID: PMC4722628 DOI: 10.1186/s13014-016-0586-x] [Citation(s) in RCA: 63] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2015] [Accepted: 01/12/2016] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND A new entity of patients with recurrent prostate cancer limited to a small number of active metastatic lesions is having growing interest: the oligometastatic patients. Patients with oligometastatic disease could eventually be managed by treating all the active lesions with local therapy, i.e. either surgery or ablative stereotactic body radiotherapy. This study aims to assess the impact of [(18)F]Choline ([(18)F]FMCH) PET/CT and the use stereotactic body radiotherapy (SBRT) in patients (pts) with oligometastatic prostate cancer (PCa). METHODS Twenty-nine pts with oligometastatic PCa (≤3 synchronous active lesions detected with [(18)F]FMCHPET/CT) were treated with repeated salvage SBRT until disease progression (development of > three active synchronous metastases). Primary endpoint was systemic therapy-free survival measured from the baseline [(18)F]FMCHPET/CT. RESULTS A total of 45 lesions were treated with SBRT. After a median follow-up of 11.5 months (range 3-40 months), 20 pts were still in the study and did not receive any systemic therapy. Nine pts started systemic therapy, and the median time of the primary endpoint was 39.7 months (CI 12.20-62.14 months). No grade 3 or 4 toxicity was recorded. CONCLUSIONS Repeated salvage [(18)F]FMCHPET/CT-guided SBRT is well tolerated and could defer the beginning of systemic therapy in selected patients with oligometastatic PCa.
Collapse
Affiliation(s)
- Francesco Pasqualetti
- Radiation Oncology, Azienda Ospedaliero Universitaria Pisana, Via Roma 55, 56126, Pisa, Italy. .,Radiation Oncology, Pisa University Hospital, Via Roma 67, 56126, Pisa, Italy.
| | - Marco Panichi
- Radiation Oncology, Azienda Ospedaliero Universitaria Pisana, Via Roma 55, 56126, Pisa, Italy.
| | - Aldo Sainato
- Radiation Oncology, Azienda Ospedaliero Universitaria Pisana, Via Roma 55, 56126, Pisa, Italy.
| | - Fabrizio Matteucci
- Radiation Oncology, Azienda Ospedaliero Universitaria Pisana, Via Roma 55, 56126, Pisa, Italy.
| | - Luca Galli
- Medical Oncology, Azienda Ospedaliero Universitaria Pisana, Via Roma 55, 56126, Pisa, Italy.
| | - Paola Cocuzza
- Radiation Oncology, Azienda Ospedaliero Universitaria Pisana, Via Roma 55, 56126, Pisa, Italy.
| | - Patrizia Ferrazza
- Radiation Oncology, Azienda Ospedaliero Universitaria Pisana, Via Roma 55, 56126, Pisa, Italy.
| | - Gabriele Coraggio
- Radiation Oncology, Azienda Ospedaliero Universitaria Pisana, Via Roma 55, 56126, Pisa, Italy.
| | | | - Lisa Derosa
- Medical Oncology, Azienda Ospedaliero Universitaria Pisana, Via Roma 55, 56126, Pisa, Italy.
| | - Martina Sollini
- Humanitas University, Via Manzoni 113, Rozzano, Milano, 20089, Italy.
| | - Lorenzo Mannelli
- Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, USA.
| | - Simona Ortori
- Radiology, Azienda Ospedaliero Universitaria Pisana, Via Roma 55, 56126, Pisa, Italy.
| | - Fabio Monzani
- Geriatrics Unit, Azienda Ospedaliero Universitaria Pisana, Via Roma 55, 56126, Pisa, Italy.
| | - Sergio Ricci
- Medical Oncology, Azienda Ospedaliero Universitaria Pisana, Via Roma 55, 56126, Pisa, Italy.
| | - Carlo Greco
- Radiation Oncology, Champalimaud Centre for the Unknown, Avenida Brasília, 1400-038, Lisboa, Portugal.
| | - Maria Grazia Fabrini
- Radiation Oncology, Azienda Ospedaliero Universitaria Pisana, Via Roma 55, 56126, Pisa, Italy.
| | - Paola Anna Erba
- Department of Translational Research and New Technologies in Medicine, Regional Center of Nuclear Medicine, University of Pisa, Via Savi 10, 56126, Pisa, Italy.
| |
Collapse
|
17
|
Lombardi G, Pace A, Pasqualetti F, Rizzato S, Faedi M, Anghileri E, Nicolotto E, Bazzoli E, Bellu L, Villani V, Fabi A, Ferrazza P, Gurrieri L, Dall'Agata M, Eoli M, Della Puppa A, Pambuku A, Berti F, Rudà R, Zagonel V. Clinical and molecular predictors of survival in elderly glioblastoma patients treated with radiotherapy and concomitant temozolomide: a multicenter study of aino (Italian Association of Neuro-Oncology). Ann Oncol 2015. [DOI: 10.1093/annonc/mdv348.13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
18
|
Sainato A, Montrone S, Coppola M, Cernusco N, Ferrazza P, Cantarella M, Cocuzza P, Mazzotti V, Morganti R, Pasqualetti F, Vasile E, Falcone A, Boggi U. 2255 Safety and effectiveness of the combination of single chemotherapeutic agent (gemcitabine) with radiotherapy in radically resected pancreatic adenocarcinoma. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31171-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
19
|
Lombardi G, Pace A, Pasqualetti F, Rizzato S, Faedi M, Anghileri E, Nicolotto E, Bazzoli E, Bellu L, Villani V, Fabi A, Ferrazza P, Gurrieri L, Dall'Agata M, Eoli M, Della Puppa A, Pambuku A, D'Avella D, Ruda R, Zagonel V. Temozolomide (TMZ) and radiation therapy (RT) combination in elderly patients with glioblastoma: A multicenter retrospective study of AINO (Italian Association of Neuro-Oncology). J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.e13003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Giuseppe Lombardi
- Department of Clinical and Experimental Oncology, Medical Oncology 1, Veneto Institute of Oncology-IRCCS, Padua, Italy
| | - Andrea Pace
- Neuro-Oncology Unit, "Regina Elena" National Cancer Institute, Rome, Italy
| | | | - Simona Rizzato
- Department of Oncology, Azienda Ospedaliero-Universitaria di Udine, Udine, Italy
| | - Marina Faedi
- Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Elena Anghileri
- Unit of Molecular Neuro-Oncology, Fondazione I.R.C.C.S. Istituto Neurologico C. Besta, Milan, Italy
| | - Elisa Nicolotto
- Department of Neuro-Oncology, University of Turin and City of Health and Science, Turin, Italy
| | - Elena Bazzoli
- Department of Neurological and Movement Sciences, University of Verona, Verona, Italy; IRCCS, Centro S. Giovanni di Dio Fatebenefratelli, Brescia, Italy, Verona, Brescia, Italy
| | - Luisa Bellu
- Department of Clinical and Experimental Oncology, Medical Oncology 1, Veneto Institute of Oncology-IRCCS, Padua, Italy
| | - Veronica Villani
- Neuro-Oncology Unit, "Regina Elena" National Cancer Institute, Rome, Italy
| | - Alessandra Fabi
- Division of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy
| | - Patrizia Ferrazza
- Department of Radiotherapy, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
| | - Lorena Gurrieri
- Department of Oncology, Azienda Ospedaliero-Universitaria di Udine, Udine, Italy
| | - Monia Dall'Agata
- Biostatistics and Clinical Trials Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Marica Eoli
- Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy, Milan, Italy
| | | | - Ardi Pambuku
- Department of Clinical and Experimental Oncology, Medical Oncology 1, Veneto Institute of Oncology-IRCCS, Padua, Italy
| | | | - Roberta Ruda
- Department of Neuro-Oncology, University of Turin and City of Health and Science, Turin, Italy
| | - Vittorina Zagonel
- Department of Clinical and Experimental Oncology, Medical Oncology 1, Veneto Institute of Oncology-IRCCS, Padua, Italy
| |
Collapse
|
20
|
Cocuzza P, Ferrazza P, Matteucci F, Fatigante L, Briganti T, Fattori B, Ursino S. EP-1145 Radiotherapy impact on swallowing function in head and neck cancer. Preliminary results. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)41137-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
21
|
Ursino S, Seccia V, Cocuzza P, Ferrazza P, Briganti T, Giusti P, Grosso M, Morganti M, Fattori B. PO-128: How does radiotherapy impact on swallowing in head and neck cancer? Short-term results of a prospective study. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)34888-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
22
|
Pasqualetti F, Bocci G, Mey V, Menghini V, Montrone S, Cocuzza P, Ferrazza P, Seccia V, Delishaj D, Orlandini C, Fabrini MG, Danesi R. Akt1 rs2498801 is related to survival in head and neck squamous cell cancer treated with radiotherapy. Anticancer Res 2015; 35:269-271. [PMID: 25550560] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
BACKGROUND Radiotherapy (RT) with or without chemotherapy (CT) plays an important role as exclusive treatment in patients with head and neck squamous cell cancer (HNSCC). Unfortunately, in some cases, benefit for patients is not recorded and only treatment-related complications are registered. MATERIALS AND METHODS Data relating to Akt1 single nucleotide polymorphism (SNP) and response to treatment of 46 patients treated with exclusive RT or RT-CT for HNSCC were evaluated. RESULTS For heterozygous patients median overall survival was 28.5 months, while for the wild-type group median overall survival was 10.9 (p=0.019). Three-year survival was 85% for mutated Akt1 homozygosis and 40% for patients with a heterozygous status (p=0.019, hazard ratio (HR)=7.960). CONCLUSION SNP of rs2498804 can recognize patients resistant to RT-CT. Further studies are needed to confirm our data and to investigate the role of Akt SNPs in HNSCC patients.
Collapse
Affiliation(s)
- Francesco Pasqualetti
- Division of Radiotherapy, Department Of Oncology, University Hospital of Pisa, Pisa, Italy
| | - Guido Bocci
- Division of Pharmacology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | - Valentina Mey
- Division of Pharmacology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | - Valentina Menghini
- Division of Radiotherapy, Department Of Oncology, University Hospital of Pisa, Pisa, Italy
| | - Sabrina Montrone
- Division of Radiotherapy, Department Of Oncology, University Hospital of Pisa, Pisa, Italy
| | - Paola Cocuzza
- Division of Radiotherapy, Department Of Oncology, University Hospital of Pisa, Pisa, Italy
| | - Patrizia Ferrazza
- Division of Radiotherapy, Department Of Oncology, University Hospital of Pisa, Pisa, Italy
| | - Veronica Seccia
- 1st Ear Nose Throat Unit, University Hospital of Pisa, Pisa, Italy
| | - Durim Delishaj
- Division of Radiotherapy, Department Of Oncology, University Hospital of Pisa, Pisa, Italy
| | | | - Maria Grazia Fabrini
- Division of Radiotherapy, Department Of Oncology, University Hospital of Pisa, Pisa, Italy
| | - Romano Danesi
- Division of Pharmacology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| |
Collapse
|
23
|
Pasqualetti F, Ferrazza P, Cocuzza P, Delishaj D, Morganti R, Pasqualetti G, Fatigante L, Fabrini M, Monzani F. P17.65 * RADIO-CHEMOTHERAPY WITH TEMOZOLOMIDE IN ELDERLY PATIENTS WITH GLIOBLASTOMA. A MONO-INSTITUTIONAL EXPERIENCE. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou174.394] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
24
|
Pasqualetti F, Ferrazza P, Cocuzza P, Fatigante L, Pasqualetti G, Fabbrini MG, Monzani F. Radio-chemotherapy with temozolomide in elderly patients with glioblastoma. A mono-institutional experience. Anticancer Res 2014; 34:4281-4285. [PMID: 25075059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
AIM The aim of the present study was to evaluate the toxicity and clinical outcome of radio-chemotherapy with temozolomide in patients with glioblastoma aged more than 65 years. MATERIALS AND METHODS The analysis was performed in 20 male and 20 female patients with a mean age at diagnosis of 71.2 (range=65-81) years, with Karnofsky performance status greater than 70 without important comorbidities. RESULTS Toxicities related to temozolomide and concomitant radiochemotherapy were similar to those reported for younger patients. The median time to progression and median overall survival of the entire cohort, from the date of diagnosis, were 10.6 (range=6.7-14.4) months and 19.3 (range=17.8-20.7) months, respectively. No significant results for overall survival analysis were found for age at diagnosis and cardiovascular risk factors, as covariates, with hazard ratios of 1.00 (95% confidence interval=0.92-1.10) and 0.9 (95% confidence interval=0.43-1.88), respectively. CONCLUSION Considering the relative good toxicity profile and the efficacy of treatment, our experience supports the use of radiochemotherapy with temozolomide in older patients with glioblastoma.
Collapse
Affiliation(s)
| | | | - Paola Cocuzza
- Radiotherapy Unit, University Hospital of Pisa, Pisa, Italy
| | | | - Giuseppe Pasqualetti
- Geriatrics Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | | | - Fabio Monzani
- Geriatrics Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| |
Collapse
|
25
|
Sainato A, Coppola M, Cernusco N, Boggi U, Pasqualetti F, Vasile E, Ferrazza P, Mazzotti V, Mosca F, Cionini L. EP-1275: Adjuvant gemcitabine and concurrent radiotherapy in resected pancreatic adenocarcinoma. Radiother Oncol 2014. [DOI: 10.1016/s0167-8140(15)31393-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
26
|
Ursino S, Ferrazza P, Cocuzza P, Cernusco L, Seccia V, Fattori B, Briganti T, Morganti R, Matteucci F, Di Martino F. EP-1103: Swallowing evaluation in head and neck cancer after IMRT: Early results of a prospective study. Radiother Oncol 2014. [DOI: 10.1016/s0167-8140(15)31221-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
27
|
Pasqualetti F, Ferrazza P, Cocuzza P, Crea F, Matteucci F, Fabrini M, Fatigante L, Bocci G, Danesi R, Greco C. EP-0997: Polymorphisms of Akt and EZH2 as predict factor of radiochemotherapy in patients with glioblastoma (GBM). Radiother Oncol 2013. [DOI: 10.1016/s0167-8140(15)33303-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
28
|
Sturchio E, Amadori A, Businaro J, Ficociello B, Ferrazza P, Colosio C, Minoia C. [Possible use of microRNAs as biomarkers for monitoring of workers exposed to asbestos]. G Ital Med Lav Ergon 2012; 34:571-573. [PMID: 23405719] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
Exposure to asbestos is the predominant cause of pleural mesothelioma (PM). The PM is a tumor difficult to diagnose, chemoresistant, and with rising Incidence. The long latency periods and the lack of preventive and therapeutic strategies for the MP, suggest that asbestos will be a social and health issue in the near future. Therefore, this overview focuses on current knowledge of epigenetic alterations and on the key role of microRNAs, small RNAs that negatively regulate gene expression, as biomarkers in PM development. Dysregulated microRNA expression pattern is specific for different cancers, including MP. MicroRNA expression analysis is a promising tool for diagnosis, typing of MP than normal tissue and other lung tumors and monitoring of new therapies. However, a better knowledge of miRNA signatures in PM is still necessary to verify the contribution of specific miRNAs as diagnostic biomarkers, also compared to different asbestos forms, exposure and subject work history.
Collapse
Affiliation(s)
- E Sturchio
- NAIL Settore Ricerca, Certificazione e Verifica - DIPIA, Via Urbana 167, 00184 Roma.
| | | | | | | | | | | | | |
Collapse
|
29
|
Gunnellini M, Graziosi L, Emili R, Bugiantella W, Ferrazza P, Cavazzoni E, Donini A, Liberati AM. [Metastatic gastric cancer successfully treated with surgery and chemotherapy. Case report]. G Chir 2010; 31:375-378. [PMID: 20843440] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
A case of long-term survivor 50-year-old man treated for advanced gastric cancer with two liver metastases is described. Patient underwent a total gastrectomy with D2 lymphadenectomy and atipic liver resection. After surgery, chemotherapy with PELF achieved a complete clinical response; six month from the fourth cycle, Ca19.9 levels slowly increased until 185 U/mL and a retro-peritoneal lymphadenopathy was detected by US. Three different chemotherapeutic combinations (FOLFOX, FOLFIRI, FOLFOX4) was administrated but two new liver recurrences spread out. From November 2007 until now, patient received 8 CDF cycles and he obtained a complete clinical response supported by persistent negativity of TC-PET scans. The radiological investigations performed after last admission in our Department for jaundice, revealed multiple liver lesions with Ca 19.9 levels of 6.766 U/mL. The patient required placement of metallic biliary endoprosthesis. He is still alive 41 month after primary surgery. We consider this case a successful example of survival increasing by integrated surgery-chemotherapy treatment but also an expression of the failure of current available therapy in the definitive cure for gastric cancer. Metastatic gastric cancer should be considered a disease treatable but not curable.
Collapse
Affiliation(s)
- M Gunnellini
- Dipartimento di Scienze Chirurgiche, Università degli Studi di Perugia
| | | | | | | | | | | | | | | |
Collapse
|
30
|
Patti F, Amato MP, Bastianello S, Caniatti L, Di Monte E, Ferrazza P, Goretti B, Gallo P, Brescia Morra V, Lo Fermo S, Picconi O, Tola MR, Trojano M. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a oncognitive decline in mildly disabled patients with relapsing—remitting multiple sclerosis. Mult Scler 2009; 16:68-77. [DOI: 10.1177/1352458509350309] [Citation(s) in RCA: 74] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The objective of this study was to assess the effects of subcutaneous (sc) interferon beta-1a (IFNβ-1a) on cognition in mildly disabled patients with relapsing—remitting multiple sclerosis (RRMS). Patients aged 18—50 years with RRMS (McDonald criteria; Expanded Disability Status Scale score ≤4.0) were assigned IFNβ therapy at the physician’s discretion and underwent standardized magnetic resonance imaging, neurological examination and neuropsychological testing at the baseline and regular intervals for up to three years. This analysis included 459 patients who received sc IFNβ-1a (44 mcg: n = 236; 22 mcg: n = 223; three-year follow up was available for 318 patients). The hazard ratio for cognitive impairment over three years (44 mcg versus 22 mcg) was 0.68 (95% confidence interval [CI]: 0.480—0.972), suggesting a 32% lower risk with the higher dose treatment. At year 3, the proportion of patients who were cognitively impaired increased slightly from 23.5% at the baseline to 24.8% in the IFNβ-1a 22 mcg treatment group, but remained stable at 15.2% in the IFNβ-1a 44 mcg treatment group. The proportion of patients with cognitive impairment at year 3 was significantly higher in the 22 mcg group than in the 44 mcg group (P = 0.03), although a trend was also seen at the baseline (P = 0.058). Multivariate logistic regression (corrected for baseline cognitive deficits) indicated that treatment with the higher dose of IFNβ-1a was predictive of lower cognitive impairment at three years (odds ratio: 0.51, 95% CI: 0.26—0.99) compared with the lower dose of IFNβ-1a. These findings suggest that sc IFNβ-1a may have dose-dependent cognitive benefits in mildly disabled patients with RRMS, and may support early initiation of high-dose IFNβ-1a treatment.
Collapse
Affiliation(s)
- F. Patti
- Multiple Sclerosis Centre Sicilia Region, First Neurology Clinic, University Hospital Catania, Catania, Italy,
| | - MP Amato
- Department of Neurology, University of Florence, Florence, Italy
| | - S. Bastianello
- Neurological Institute, IRCCS Fondazione C. Mondino, Pavia, Italy
| | - L. Caniatti
- U.O. Neurology, Department of Neuroscience and Rehabilitation, Azienda Universita-Ospedale, S. Anna, Ferrara, Italy
| | - E. Di Monte
- Department of Neurological and Psychiatric Sciences, University of Bari, Bari, Italy
| | - P. Ferrazza
- Opera CRO Scientific Advisor Board, Genoa, Italy/Neuromed Clinical Department, Pozzilli, Italy
| | - B. Goretti
- Department of Neurology, University of Florence, Florence, Italy
| | - P. Gallo
- Multiple Sclerosis Centre Veneto Region, First Neurology Clinic, University Hospital, Padova, Padova, Italy
| | | | - S. Lo Fermo
- Multiple Sclerosis Centre Sicilia Region, First Neurology Clinic, University Hospital Catania, Catania, Italy
| | - O. Picconi
- Public Health Agency of Regione Lazio, Rome, Italy
| | - MR Tola
- U.O. Neurology, Department of Neuroscience and Rehabilitation, Azienda Universita-Ospedale, S. Anna, Ferrara, Italy
| | - M. Trojano
- Department of Neurological and Psychiatric Sciences, University of Bari, Bari, Italy
| | | |
Collapse
|
31
|
Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Goretti B, Caniatti L, Di Monte E, Ferrazza P, Brescia Morra V, Lo Fermo S, Picconi O, Luccichenti G. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing–remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study. Mult Scler 2009; 15:779-88. [DOI: 10.1177/1352458509105544] [Citation(s) in RCA: 146] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Background Cognitive impairment is a common symptom of multiple sclerosis (MS), but the association between cognitive impairment and magnetic resonance imaging (MRI) disease measures in patients with relapsing–remitting (RR) MS is unclear. Objectives To study the prevalence of cognitive impairment and its relation with MRI disease measures in mildly disabled patients with RRMS. Methods Patients aged 18–50 years with RRMS (McDonald criteria) and an Expanded Disability Status Scale (EDSS) score ≤4.0, who were enrolled in the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study, underwent baseline standardized MRI complete neurological examination and neuropsychological testing. Results A total of 550 patients were enrolled, 327 of whom underwent MRI assessments. Cognitive impairment (impaired performance in ≥3 cognitive tests) was present in approximately 20% of all patients and in the subgroup who underwent MRI. T2 hyperintense and T1 hypointense lesion volumes were significantly higher in patients with cognitive impairment (defined as impaired performance on at least three tests of the Rao’s battery) than those without. EDSS score was also significantly higher in cognitively impaired than in cognitively preserved patients. Disease duration, depression, and years in formal education did not differ significantly between cognitively impaired and cognitively preserved patients. T2 lesion volume, performance intelligence quotient, and age were significant predictors of cognitive impairment in this population. Weak correlations were found between performance on individual cognitive tests and specific MRI measures, with T1 and T2 lesion volumes correlating with performance on most cognitive tests. Conclusions Cognitive impairment occurs in approximately one-fifth of mildly disabled patients with MS and is associated with specific MRI disease measures. Assessment of cognitive function at diagnosis could facilitate the identification of patients who may benefit from therapeutic intervention with disease-modifying therapies to prevent further lesion development.
Collapse
Affiliation(s)
- F Patti
- Department of Neurosciences, University of Catania, Catania, Italy
| | - MP Amato
- Department of Neurology, University of Florence, Florence, Italy
| | - M Trojano
- Department of Neurological and Psychiatric Sciences, University of Bari, Bari, Italy
| | - S Bastianello
- Neuroradiology Unit, Neurological Institute I.R.C.C.S. “Fondazione C. Mondino”, University of Pavia, Pavia, Italy
| | - MR Tola
- Department of Neurosciences and Rehabilitation, University of Ferrara, Ferrara, Italy
| | - B Goretti
- Department of Neurology, University of Florence, Florence, Italy
| | - L Caniatti
- Department of Neurosciences and Rehabilitation, University of Ferrara, Ferrara, Italy
| | - E Di Monte
- Department of Neurological and Psychiatric Sciences, University of Bari, Bari, Italy
| | - P Ferrazza
- Opera CRO Scientific Advisor Board Neuromed Clinical Department, Genoa, Italy
| | - V Brescia Morra
- Department of Neurological Sciences, Second University of Naples, Naples, Italy
| | - S Lo Fermo
- Department of Neurosciences, University of Catania, Catania, Italy
| | - O Picconi
- Public Health Agency of Regione Lazio, Rome, Italy
| | - G Luccichenti
- Department of Radiology, IRCCS Fondazione Santa Lucia, Rome, Italy
| | | |
Collapse
|
32
|
Midiri G, Lombardi A, Tesoriere A, Ferrazza P, Luzzatto L, Bosco D, Soda G, Di Paola M, Melis M. [Differential diagnostic problems between nodular fasciitis and soft-tissue sarcomas. A review of the literature and a case report]. G Chir 2000; 21:49-52. [PMID: 10732382] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
Abstract
After a review of literature and the report of a case with intrathoracic location, the authors consider present criteria for a correct diagnosis of low grade soft tissue sarcoma, when the possibility of nodular fasciitis is under evaluation. Nodular fasciitis is a benign pathology up to day not well characterised from the clinical and pathological point of view. The authors conclude that differential diagnosis between low grade soft tissue sarcoma and nodular fasciitis is frequently possible only on the basis of clinical course evaluation; otherwise the management may be inadequate.
Collapse
Affiliation(s)
- G Midiri
- Dipartimento di Scienze Chirurgiche e Tecnologie Mediche Applicate, Università degli Studi La Sapienza, Roma
| | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Covotta L, Tesoriere A, Ferrazza P, Di Paola M, Regolo L, Diomedi Camassei F, Assenza M, Lombardi A, Di Paola M. [Desmoids associated with multiple familial polyposis: description of a clinical case]. G Chir 1998; 19:223-6. [PMID: 9677775] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
The Authors report a case of great desmoid tumor of the abdominal wall with intestinal adhesions and enterocutaneous fistula, in a patient with Gardner's syndrome, who underwent total colectomy with ileorectal anastomosis. The patient was treated at first with non steroidal antiinflammatory drugs, then with local chemotherapy. The Authors performed a second surgical procedure resecting the tumor and opening a temporary ileostomy. Despite of these treatment patient showed a local recurrence. Desmoid tumor is a neoplastic benign lesion arising from aponeurotic muscle tissue. Local infiltration and post-operative recurrence are very common. Several surgical and medical treatments are proposed, but they are not totally effective. Surgical treatment might be radical, with wide resection to reduce local recurrences. Radiotherapy and chemotherapy are second choice treatments.
Collapse
Affiliation(s)
- L Covotta
- Istituto di IV Clinica Chirurgica Generale e Terapia Chirurgica, Università degli Studi La Sapienza, Roma
| | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Lombardi A, Ferrazza P, Castaldi F, Covotta L, Tesoriere A, Urbano V, Midiri G. [Acute hepatic necrosis in a patient treated with cyproterone acetate]. G Chir 1998; 19:161-3. [PMID: 9628065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
The Authors report a case of prostatic carcinoma in a 84 year old male, treated with cyproterone acetate (CPA), complicated by a fatal fulminant hepatitis. He was admitted with a mixed jaundice followed by a derange of all liver function tests. Serological markers for hepatitis were negative. Ultrasonography and CT revealed no hepatic abnormality but gallstones and dilatation of principal bile duct with a terminal stricture. By the endoscopic retrograde cholangiography and sphincterotomy we put an external drain tube. He died 9 days after admission. Fatal hepatis due to CPA is a very rare complication but all patients on anti-androgenic drugs should have liver function closely monitored. CPA must be discontinued immediately at the first derange of liver function tests.
Collapse
Affiliation(s)
- A Lombardi
- Istituto di IV Clinica Chirurgica, Università degli Studi La Sapienza, Roma
| | | | | | | | | | | | | |
Collapse
|
35
|
Ferrazza P, Assenza M, Diomedi Camassei F, Lombardi A, Di Paola M. [Indications for splenectomy in Gaucher's disease. Case report]. G Chir 1997; 18:209-11. [PMID: 9303635] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Gaucher's disease is a rare metabolic disorder characterized by the lack of beta-glucocerebrosidase enzyme. In this case report a 26-year-old male patient was, first diagnosed as having splenomegaly and a huge haemangioma, therefore managed by total splenectomy. Histologic examination and specific colouring techniques using PAS and Black Sudan dyes allowed the diagnosis of Gaucher's disease. Preoperative diagnosis is hence fundamental to establish the correct management procedure, which currently may be surgical or medical and/or combined. In fact, following the diagnosis the second step includes the decision-making about splenectomy. Other therapeutic approaches are enzyme replacement therapy and genic therapy. The first may be combined to partial splenectomy, while the latter still needs further evaluations.
Collapse
Affiliation(s)
- P Ferrazza
- Istituto di IV Clinica Chirurgica, Cattedra di Chirurgia Generale, Università degli Studi La Sapienza, Roma
| | | | | | | | | |
Collapse
|
36
|
Tripodi M, Citarella F, Guida S, Galeffi P, Gallo E, Ferrazza P, Amicone L, Mariani R, Longobardi C, Fantoni A. Molecular studies on DNA sequences coding for factor VII and factor XII of human coagulation. Ital J Biochem 1986; 35:328-32. [PMID: 3542896] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
In this paper are described the immunological and molecular procedures that have allowed the identification and the nucleotide sequence characterization of recombinant cDNA coding for factor XII of human coagulation and have suggested the possible identification of other cDNA clones as coding for factor VII of human coagulation.
Collapse
|